47 results
Primary: To evaluate the safety and toxicity of TIL therapy in patients with metastatic NSCLC preceded by chemotherapy with or without immunotherapy.Secondary: Clinical response according to RECIST 1.1 criteria and immune response criteria (irRC).…
Primary: Safety run-in part (part 1):• Recommended Phase 3 dose regimen (RP3R) of canakinumab in combination with pembrolizumab plus chemotherapy. Double-blind, randomized, placebo-controlled part (part 2):• Progressive free survival (PFS) between…
The primary objective of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progressionfree survival (PFS) (by independent imaging…
To evaluate efficacy of image-guided de-escalating chemotherapy in the presence of dual HER2-blockade with Herceptin® and pertuzumab in HER2-positive breast cancer, as measured by three-year event-free survival.Secondary objectives• To evaluate 3-…
Primary Objective• To compare the event-free survival (EFS) by blinded independent central review (BICR) in Arm A (vs Arm B participantsSecondary Objectives• To compare the overall survival (OS) in Arm A vs Arm B participants• To assess the…
To compare two (standard) treatment regimens in patients with KRAS mutated advanced stage NSCLC as first line treatment.
This study will evaluate the efficacy, safety, and PK of enfortumab vedotin in combination with pembrolizumab, with or without platinum-containing chemotherapy, versus standard of care gemcitabine plus platinum-containing chemotherapy in subjects…